Retinal detachments in the pediatric population
Nicola Yi’an Gan¹, Wai-Ching Lam²,³

Abstract:
In this review, we present a concise summary of the more commonly seen types of retinal detachments (RDs) that one can encounter in pediatric patients. A spectrum of diseases from rhegmatogenous RD in Stickler syndrome, Marfan syndrome, and choroidal coloboma to exudative RD in Coats disease, to tractional RD in persistent fetal vasculature, and combined RDs in familial exudative vitreoretinopathy are described with the management pearls for each.

Keywords:
Pediatric, retinal detachment, scleral buckling, vitrectomy, vitreoretinal surgery

Introduction
Retinal detachments (RDs) in the pediatric population span a variety of congenital and acquired conditions with some not commonly seen in adults. In this review, we describe and illustrate the more commonly encountered types of rhegmatogenous RDs (RRDs), tractional RDs, and exudative RDs and highlight important pearls in the diagnosis and management of each.

Rhegmatogenous Retinal Detachments
Epidemiology and clinical presentation
The incidence of RRD in children is low. The causes of RRD can be divided into traumatic and nontraumatic. Nontraumatic causes include (i) myopia; (ii) hereditary congenital anomalies (more common examples include Stickler syndrome, Marfan syndrome, and X-linked retinoschisis); (iii) nonhereditary developmental anomalies, e.g., choroidal coloboma, cicatricial retinopathy of prematurity (ROP); and (iv) previous intraocular surgery.[¹-⁶]

Delayed diagnosis is a significant feature of pediatric RRDs. Compared to adults, children with nontraumatic RRDs usually present at a later stage and with RD of undetermined duration. At presentation, these detachments are usually macula-involving or have proliferative vitreoretinopathy (PVR). The incidence of PVR at presentation has been reported in various studies to range from 40% to 45%.[²,⁷] Occasionally, a child may present late with sensory strabismus as a result of an undiagnosed chronic RD. Bilateral involvement has also been reported to be more common in pediatric nontraumatic RRDs, with a range of 15%–22%.[²,³]

Conversely, traumatic RRDs usually present acutely and with a known duration. In a large series of 127 eyes, Soheilian et al.[⁵] reported a statistically significant higher male-to-female ratio in traumatic RRDs (9.8:1) but no significant difference in nontraumatic cases.[²] In a retrospective case series of 88 eyes in patients aged 0–16 years by Lee et al.,[⁸] 53% of RRDs were related to trauma and 44% of retinal breaks were retinal dialyses. Retinal dialysis is most often located in the inferotemporal quadrant, which may become symptomatic years after the trauma. In this series, 76%
Performing a pneumatic retinopexy (PR) described a pedigree combining hereditary peripheral retinal changes. Alterations in the structure of the vitreous with abnormal vitreoretinal adhesions can predispose to RRD in these eyes. In many of these syndromes, systemic abnormalities affecting the joints and skeletal systems are also present.

**Stickler syndrome**

Stickler et al.\(^1\) described a pedigree combining ocular, facial, palatal, and skeletal changes in 1965. Prominent features of this disorder include generalized arthropathy, cleft palate, flat face, hearing loss, and spondyloepiphyseal dysplasia. Abnormalities of the vitreous gel structure are pathognomonic of this disorder. The inheritance is usually in an autosomal dominant pattern, but it can also occur sporadically.

Type I Stickler syndrome has a membranous vitreous phenotype with a well-defined retrolenticular fibrillar condensation separated from a larger and more posterior empty vitreous space (Type I vitreous). This type is most common and is associated with gene mutations for synthesis of collagen Type II (COL2A1).\(^2,3\) The less common Type II Stickler syndrome has a beaded vitreous phenotype (Type 2 vitreous) and is associated with mutation in the COL11A1 gene which codes for Type XI collagen. Type III Stickler syndrome has no ocular findings and is caused by mutation in the COL11A2 gene.

**Nonocular features**

Facial features of the patients with Stickler syndrome include abnormal nasal, maxillary, and mandibular bone development. Patients usually have an underdeveloped nasal bone with a saddle nose. Other skeletal abnormalities include epiphyseal dysplasia, lax joints, and early-onset progressive arthritis.\(^4,5,6\) Neurosensory hearing loss also affects most patients over time.\(^7\)

**Ocular features**

Ocular abnormalities in Stickler syndrome involve both the anterior and posterior segment. Early-onset cataract is common, with a characteristic lamellar wedge-shaped lens opacity occurring symmetrically in both eyes, reflecting the embryologic abnormality in this syndrome.\(^8,9\) Patients are usually highly myopic with peripheral retinal thinning and retinal breaks, including giant retinal tears. In Type I Stickler syndrome, the vitreous gel is typically optically empty with the presence of a fibrillar retrolenticular membrane extending to the pars plana and the peripheral retina. In Type II Stickler syndrome, vitreous changes present are beaded condensations in the retrolenticular space, with peripheral lattice degeneration and perivascular pigmentation.

RRD is the most serious ocular complication of Stickler syndrome and may occur early in life. Eight percent of affected children have RRD between the ages of 0 and 9 years and 26% between the ages of 10 and 19 years.\(^10\)

---

**Rhegmatogenous retinal detachments associated with congenital developmental anomalies**

**Epidemiology and clinical presentation**

The reported incidence of congenital developmental anomalies as a cause of pediatric RRD ranges from 12% to 56%.\(^11,12,13,14\) In studies done in East Asian countries, e.g., Taiwan, the incidence reported is lower at 12%-17% as there is a higher incidence of myopia and associated RRD in East Asian populations.\(^15,16\)

In a retrospective case series of 127 eyes, Soheilian et al.\(^17\) reported that congenital developmental anomalies comprise 52.5% of RRDs in children below the age of 10 years, with an overall incidence of 39.3%. Hereditary vitreoretinopathies comprise the majority with Stickler syndrome being the most common.\(^18,19\) Hereditary vitreoretinopathies are a group of disorders characterized by abnormally appearing vitreous gel associated with peripheral retinal changes. Alterations in the structure
The incidence of RRD varies between different reports and ranges between 10% and 73%. There is a propensity for giant retinal tear formation [Figure 1], but a spectrum of retinal breaks may be seen. A detailed examination of both eyes is mandatory in patients with Stickler syndrome, with the need to consider prophylactic treatment of high-risk peripheral retinal pathology in the fellow eye. Fellow eye examination may reveal lattice degeneration, pigmented retinopathy, retinal holes, or RD. Bilateral RDs are common and range from 39% to 51%.

Ang et al., 2008 did a large retrospective study on 204 Type I Stickler syndrome patients and concluded that prophylactic treatment in the eyes unaffected by RD (either unilateral or bilateral 360° cryotherapy applied to the post-orbital retina) reduced the risk of developing a retinal detachment. They published a statistically significant difference in the incidence of RD in patients with Type I Stickler syndrome without prophylaxis (73%, 81 of 111) versus failure of prophylaxis in patients with bilateral cryotherapy (5 of 62 [8%]) and patients with unilateral cryotherapy (3 of 31 [10%]). However, this approach is unconventional and based on one study. We prefer to carry out prophylactic treatment only to high-risk lesions such as lattice degeneration.

Finally, screening the family members of Stickler syndrome patients is also an important strategy to identify other affected members for prophylaxis or early treatment.

Marfan syndrome
Marfan syndrome is an autosomal dominant disorder that involves the ocular, cardiovascular, and musculoskeletal systems. The genetic defect is found on the long arm of chromosome 15, known as fibrillin 1 gene. The pathogenesis lies in the defect in production of fibrillin, a glycoprotein that is an essential component of the microfibril assembly in the extracellular matrix. Microfibrils are essential in the deposition of elastin, which is present in the lens, zonules, and joint capsule. Fibrillin is also found in ocular structures such as the lamina cribrosa, sclera, choroid, and Bruch’s membrane. The revised Ghent nosology is most widely used to diagnose this syndrome.

Nonocular features
The cardiovascular manifestations include aortic dilatation and dissecting aneurysms. Mitral valve prolapse affects 60%–70% of patients. Musculoskeletal features include tall stature (>95th percentile by age/race/sex), joint laxity, hyperextensible joints, arachnodactyly or long fingers, dolichostenomelia or long limbs, scoliosis, pectus deformities of the anterior chest wall, congenital contractures of the digits and elbows, and generalized osteopenia.

Ocular features
Nontraumatic ectopia lentis [Figure 2] is the most common ocular presentation in Marfan syndrome and is seen in 50%–80% of patients. The subluxation is usually towards the superotemporal meridian. Patients usually have poorly dilating pupils and iris transillumination defects. Axial myopia is common, and Maumenee found that 21% of eyes had myopia of 7 diopters or more.

Retinal detachment occurs in 5%–11% of these Marfan patients and increases to 8%–38% in those who have ectopia lentis or who have undergone cataract surgery. Most develop RD at a young age. In a large series, it has been reported that 70% of 160 patients with RD were below the age of 20 years. Bilateral RD is common and may reach 70%.

Due to the high incidence of bilaterality, careful evaluation and monitoring of the fellow eye is
recommended and prophylactic treatment may be justified.\textsuperscript{41} Patients with Marfan syndrome tend to have more complex RD including giant retinal tears. The main difference between patients with Marfan syndrome versus Stickler syndrome is that the congenital vitreous anomaly seen in Stickler syndrome is absent. The pathogenesis of RD in Marfan syndrome is related to posterior vitreous detachment. The incidence of detachment is related to the level of myopia, and these patients have vitreous degenerative changes similar to that found in myopic eyes.\textsuperscript{37,42} Lens subluxation and lens extraction are also risk factors for developing RD.\textsuperscript{38}

Retinal detachments in Marfan syndrome can be a surgical challenge. Special considerations include a poorly dilating pupil and subluxed lens that can sometimes limit visualization and assessment of the retina. In small pupils, iris retractors may be of benefit. In eyes with minimal lens subluxation and well-dilated pupils, the RD can be successfully repaired using standard scleral buckling techniques. However, complex RDs with severe lens subluxation are better managed with pars plana lensectomy, vitrectomy, and endotamponade using long-acting gas or silicone oil, with or without scleral buckling. With current advanced surgical techniques, visualization, and illumination systems, the anatomic success rates reported for repair of RDs in Marfan syndrome are comparable with non-Marfan eyes at 75\%–86\%.\textsuperscript{40,41}

**Choroidal coloboma**

Coloboma of the choroid is a rare condition occurring in only 0.14\% of the general population\textsuperscript{43} [Figure 3]. The prevalence of RRDs in this group of eyes has been reported to be 23\%–40\%.\textsuperscript{44,45}

A choroidal coloboma is caused by incomplete closure of the embryonic fissure at the 7th week of gestation. It may also be associated with colobomas of the eyelid and iris. Histologically, the choroidal coloboma area is deficient in the normal choroid, retinal pigment epithelium (RPE), and retina. The retina splits into two layers near the margin of the coloboma; the inner neuroblastic layer shows central continuation of the intercalary membrane (ICM) to the coloboma, whereas the outer neuroblastic layer turns back, becomes disorganized, and fuses with the RPE. The retina gradually thins into the ICM, with a high chance of breaks in the ICM developing along the edge of the coloboma or towards the center.\textsuperscript{46,47} Retinal breaks within such abnormal tissue are hard to identify because of the lack of contrast. With the use of optical coherence tomography, RRDs in colobomatous eyes have been found to be most commonly caused by a combination of a break in the ICM with the presence of communication between the sub-ICM space and the subretinal space\textsuperscript{46–48} [Figure 4].

Repair of these coloboma-associated RDs remains a surgical challenge to date, especially if the optic nerve is involved and if there are associated ocular anomalies such as microphthalmia, cataract, or lens coloboma.\textsuperscript{49} In retinal detachments occurring in a colobomatous eye that do not involve the area of the coloboma, surgical repair principles are the same. Several operative techniques of coloboma-associated RD have been described.

Previously, Wang and Hilton\textsuperscript{49} advised buckling the margin of the coloboma with two radial buckles. Patnaik and Kalsi\textsuperscript{50} reported success in a patient in which they buckled the entire coloboma. However, with the advent of small gauge pars plana vitrectomy, most coloboma-related RDs are now repaired via the intraocular approach. The identification of breaks in the ICM is easier with intraocular visualization during pars plana vitrectomy.\textsuperscript{51} Direct closure of the breaks with cyanoacrylate glue has been described.\textsuperscript{52} However, in most cases, direct closure is not possible. Glue is not effective in a split or atrophied ICM as only the inner layer of the schisis will be sealed and progressive atrophy may enlarge the hole as the ICM contracts. The best approach, therefore, would be to isolate the coloboma from the rest of the retina.\textsuperscript{48}

The same principles of retinal detachment repair apply. Both meticulous removal of vitreous attachments and incision of the ICM to weaken it are important steps to relieve traction on the break within the ICM. Laser retinopexy can then be applied around the coloboma margin to create a border of chorioretinal adhesion. It is difficult to create chorioretinal adhesion directly around holes in the ICM as the choroid and RPE are usually absent. After creating a circumferential barrier of chorioretinal adhesion, endotamponade with gas\textsuperscript{53} is preferred as silicone oil\textsuperscript{51,54} has the potential risk of getting into the subretinal space through the colobomatous defect.

In eyes where the coloboma involves the optic nerve, peripapillary endolaser photocoagulation through the papillomacular bundle may result in laser-induced retinal nerve fiber layer damage, leading to poor visual improvement even with retinal reattachment.\textsuperscript{55} In these eyes, underlying amblyopia also limits functional recovery. McDonald et al.\textsuperscript{56} suggested that postoperative laser treatment through the papillomacular bundle may be preferable. However, this is not easily performed in the clinic, and recurrent RD can occur.

**Exudative Retinal Detachments**

**Coats disease**

*Epidemiology and clinical presentation*

Coats disease is an idiopathic retinal vascular disorder, characterized by retinal telangiectasia and aneurysms
that can progress to intraretinal and subretinal exudation, with later development of exudative RD.

This disease was first described by Coats in 1908, a curator of the Royal London Ophthalmic Hospital. Dr. Coats observed that the disorder had a slow and insidious onset and occurred most frequently in one eye of otherwise healthy boys. The main findings were raised patches of flocculent, yellow-white exudates, usually in the posterior pole, and always beneath retinal vessels. Telangiectatic and aneurysmal changes seen in the retinal vessels were often described as “light-bulb telangiectasia.”

Microscopically, vascular anomalies, retinal hemorrhage, cystic retinal degeneration, and subretinal accumulations of fibrous tissue were seen. The disease was seldom quiescent and progressed slowly to exudative RD, cataract, glaucoma, and phthisis bulbi. Although largely thought to be idiopathic, there have been more recent findings that demonstrate a relationship between Coats disease and NDP gene mutations, associated with Norrin deficiency. In a population-based study in the United Kingdom, Morris et al. estimated the population incidence to be 0.09/100,000. All cases were unilateral and 85% were male. A large retrospective consecutive case series of 150 patients in the USA conducted by Shields et al. found that Coats disease was diagnosed at a median age of 5 years (range, 1 month to 63 years), occurred mainly in males (76%, 114 of 150), and was unilateral in 95% (142 of 150 patients). There was no predilection for race or laterality. The most common referral diagnoses were Coats disease in 64 cases (41%) and retinoblastoma in 43 (27%). The first symptom or sign was decreased visual acuity in 68 cases (34%), strabismus in 37 (23%),
and leukocoria in 31 (20%). Thirteen patients (8%) were asymptomatic. Visual acuity at presentation was poor in most, ranging from 20/200 to no light perception in 121 eyes (76%). The anterior segment was normal in 142 eyes (90%).

Posterior segment findings in patients with Coats disease include retinal telangiectasia, intraretinal exudation, exudative RD, retinal macrocysts, retinal hemorrhage, vasoproliferative tumor, optic disc, and retinal neovascularization. [62] Shields et al. [62] further classified Coats disease into five stages [Table 1 and Figure 5].

The variability of symptoms in Coats disease means that the clinical presentation can be similar to several other ophthalmic conditions. The most important lesion to be ruled out is retinoblastoma as it is the most common primary intraocular malignancy in children and can be fatal when left untreated. Coats disease misdiagnosed as retinoblastoma has also been reported to be the most common cause of wrongful enucleation. [61]

Other common differential diagnoses that should be considered include familial exudative vitreoretinopathy (FEVR), hemangioblastoma von Hippel, pars planitis, and incontinentia pigmenti, which are more often bilateral, as well as ocular toxocariasis and persistent fetal vasculature (PFV), which tend to be unilateral. [63]

**Diagnostic modalities**

In majority of cases, it is possible to reach a diagnosis clinically; however, in some, ancillary investigations may be useful, including fundus fluorescein angiography (FFA), B-scan ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI).

FFA plays an important role in both diagnosis and monitoring of disease progression. Retinal telangiectasias cause early hyperfluorescence with leakage and exudation causes blocked fluorescence. Aneurysmal dilatations will be visible as “light bulb” telangiectasia. Areas of retinal ischemia will show hypofluorescence or capillary dropout [61, 64] [Figure 6].

**Table 1: Shields classification of Coats disease**

| Stage 1       | Retinal telangiectasia only |
|---------------|----------------------------|
| Stage 2       | Telangiectasia and exudation |
| -2A           | Extrafoveal exudation       |
| -2B           | Foveal exudation            |
| Stage 3       | Exudative RD                |
| -3A           | Subtotal RD                 |
| -3B           | Total RD                    |
| Stage 4       | Total RD and glaucoma       |
| Stage 5       | Advanced end-stage disease  |

RD = Retinal detachment

B-scan ultrasonography can be useful as a diagnostic tool in eyes with a poor view of the retina. Typical features of Coats disease on ultrasound are subretinal opacities due to cholesterolosis present from the exudates, as well as retinal detachment. [65] Most critically, it can be used to rule out retinoblastoma, which is typically seen as a hyperechoic tumor with an irregular outline, and often with calcium deposits, which are seen as highly reflective foci within the tumor [Figure 7].

A CT scan of the orbits is also useful to rule out retinoblastoma as it can visualize solid tumors and calcifications. However, this modality of screening is controversial in children due to the radiation exposure, and not all patients with retinoblastoma present with calcified tumors. It should be noted that there have been reports of a submacular calcified nodule forming in up to 20% of eyes with advanced Coats disease. [66]

An MRI scan of the orbits is very useful in the diagnosis of advanced Coats disease but may have less use during the initial stages. MRI is superior to CT in ruling out retinoblastoma as the difference between subretinal exudation and a solid mass is clearer on MRI. [67] Specifically, the exudate in Coats disease is hyperintense, on both T1-weighted and T2-weighted MRI, whereas in retinoblastoma, a T1-weighted image will show a hyperintense mass, but T2-weighted image shows a hypointense mass. [68]

Figure 5: (a and b) Coats disease Stage 2 – retinal telangiectasia and exudation
**Management**

The main treatment goal in Coats disease is to preserve vision and the globe, by eradication of all abnormal vasculature and areas of non-perfusion to reduce further exudation and retard the progression of the disease.

Patients with Stage 1 disease are usually observed. In Stage 2 disease, the aim is to directly ablate the retinal telangiectasias and aneurysms by laser or cryopexy to reduce further exudation and induce resorption of exudates. Favorable outcomes are more likely in early stages where 1–2 retinal quadrants are involved and in cases where treatment can be applied over areas of vascular, rather than exudative changes. Multiple laser photocoagulation treatments are often needed to contain the vascular activity completely, and recurrences may be seen over a decade after successful treatment.

A population-based prospective study performed across the United Kingdom in 2010 showed that up to 92% of patients with Coats disease are managed with laser photocoagulation, with cryotherapy being used mainly as a second-line or as an adjunctive treatment.

In patients with more advanced disease (Stage 3 and 4), no gold standard treatment currently exists. If the retinal detachment is shallow, laser photocoagulation and/or cryotherapy may be performed alone. Laser photocoagulation is applied directly to the telangiectatic vessels in areas with little or no subretinal fluid (SRF). Cryotherapy is occasionally added, using a double freeze-thaw method, where the lesion is too thick for laser treatment, or the detachment is shallow enough to allow approximation of the cryoprobe to the telangiectasia using scleral indentation. Cryotherapy applied to more than two quadrants can increase the exudative process (ablatio fugax); therefore, it is advisable not to apply cryotherapy to more than two quadrants in one treatment session. Other complications of cryotherapy include posterior subcapsular cataract and proliferative vitreoretinopathy.

In eyes with more extensive retinal detachment in which laser or cryotherapy alone would be ineffective, surgical repair of the RD may be combined with laser photocoagulation or cryotherapy. Initial reattachment of the retina to the RPE may be achieved via external drainage of SRF. Ablation of abnormal telangiectatic vessels can then be carried out once SRF is drained.

Adam et al. recommended a surgical approach of “less is more” in patients with extensive exudative RD. They treated patients with minimally invasive surgery that involved establishment of a pars plana vitreous infusion line of balanced salt solution, external drainage of SRF, and initial reattachment of the retina to the RPE.
via a posterior sclerotomy, and cryopexy of retinal telangiectasia with a double freeze-thaw technique. This approach was first described by Harris in 1970 and has since been reported in several other papers with the addition of a vitreous infusion to the procedure as described. Several authors have reported more invasive techniques, including vitrectomy, posterior retinotomy, use of intraocular silicone oil or gas, and scleral buckling in advanced Coats disease. However, in their experience, Adam et al. found that these more complex and invasive techniques did not enhance anatomical and functional outcomes in patients presenting with advanced disease and poor vision.

Despite treatment to ablate the vascular anomalies and induce resorption of SRF, Stage 3 disease often progresses to Stages 4 and 5. In advanced end-stage Coats disease (Stage 5), the aim of treatment is to maximize useful vision, ensure comfort, and preserve cosmesis. Macular damage from ischemia or significant exudation is often irreversible at this stage, and visual potential is severely limited. In patients with a painless eye, observation is usually recommended. Often, patients develop rubeosis iridis and neovascular glaucoma, leading to a painful blind eye. In these cases, transscleral diode cyclophotocoagulation may be carried out, and occasionally, evisceration or enucleation is necessary.

Recently, intravitreal triamcinolone and anti-vascular endothelial growth factor (VEGF) agents have also been used as adjuvant therapy to improve anatomic and visual outcomes. Othman et al. demonstrated an improvement in visual acuity as well as resorption of SRF and macular exudates in 15 consecutive patients treated with intravitreal triamcinolone in combination with laser photocoagulation and/or cryotherapy. However, the use of intravitreal triamcinolone has been restricted largely due to the common side effects of cataract formation and glaucoma.

The role of VEGF in the pathogenesis of Coats disease and the development of vascular abnormalities were noted in 2007 by Sun et al. who observed elevated VEGF levels in a young male with Stage 4 Coats disease. Kase et al. later hypothesized that VEGF could have a role in the pathogenesis and progression of the disease not only by inducing vascular abnormalities but also by contributing to exudation.

In early disease, anti-VEGF treatment alone has been described with good results. However, in more advanced stages of the disease, anti-VEGF treatment alone has transient efficacy. Combination therapy with laser photocoagulation and/or cryotherapy has been described in patients with early (Stages 1 and 2) as well as advanced (Stages 3 and 4) Coats disease with treatment success. As an adjunctive treatment, it seems to reduce macular edema and exudates, improve or even stabilize visual acuity, and enhance the regression of abnormally dilated vessels.

Lin et al. administered intravitreal bevacizumab followed by cryotherapy of vascular abnormalities in a patient aged 6 months and with Stage 3B Coats disease. This resulted in resolution of the exudative RD and subsequent partial resolution of the exudation at 1 year. Another group reported the combined use of intravitreal bevacizumab with laser photoacoagulation in two patients aged 2 and 7 years with Stage 4 disease. This resulted in reduced exudation and posterior pole retinal reattachment at 6 months.

Stanga et al. recently published a retrospective case review of eight eyes in eight children with advanced Coats disease presenting with total or subtotal RD. All eyes initially underwent transscleral drainage of exudative SRF followed by 1–2 intravitreal injections of bevacizumab and laser photoacoagulation. Patients were followed for up to 60 months. In all eyes, subretinal fluid was completely eliminated after surgical drainage and intravitreal bevacizumab, with resolution of subretinal exudates and total retinal reattachment after laser treatment. They suggested that this therapeutic approach is successful in treating patients with advanced exudative detachment in Coats disease without the need for vitrectomy.

The benefits of anti-VEGF therapy, however, must be weighed against the possible risks and its limited effect. Ramasubramanian and Shields advised caution with the use of bevacizumab after the development of vitreoretinal fibrosis in four of the eight patients treated with cryotherapy and intravitreal bevacizumab injection, with three eyes progressing to tractional RD.

**Tractional Retinal Detachments**

**Persistent fetal vasculature**

**Clinical presentation**

Persistent fetal vasculature (PFV) is a term used to describe a set of congenital vascular malformations in which different components of the intraocular fetal vasculature persist after birth. Most are sporadic but can be inherited as an autosomal dominant or recessive trait. These variants include persistent pupillary membrane, iridohyaloid vessels, Mittendorf dot, the vasa hyaloidea propria, muscae volitantes, the hyaloid artery, Bergmeister papilla, congenital nonattachment of the retina, macular hypoplasia and dysplasia, optic nerve hypoplasia and dysplasia, and malformations in the shape and size of the cornea and globe.
These PFV malformations may be divided into three categories: anterior, posterior, or both based on the anatomical location of the vascular malformations. In anterior PFV, the most common features include retrolental fibrovascular membrane, elongated ciliary processes, cataract, and microphthalmia. In posterior PFV, clinical features include vitreous membrane and stalk, retinal fold, congenital nonattachment of the retina, hypoplastic optic nerve and macula, and microphthalmia [87] [Figure 8].

Congenital non-attachment of the retina associated with PFV has also been called congenital retinal septum [88] ablatio falciformis congenita [89] or posterior persistent hyperplastic primary vitreous as it is most commonly known [90,91]. This is a specific type of tractional retinal detachment that is present at birth, after which it may or may not be progressive [90]. Spontaneous reattachment is rare. Histological studies have shown that it is caused by traction from persistent components of the fetal intraocular vasculature and possibly by neuroectodermal components of the primary vitreous [92].

The primary pathogenesis is adhesion to and lack of separation of the primary vitreous and its blood vessels from a portion of the inner layer of the developing optic cup. The secondary vitreous is unable to form, and traction from adherent persistent fetal vasculature then causes RD [67].

Primary malformations of the macula in posterior PFV include hypoplasia and dysplasia with failure of development of the foveal pit [93,94]. Secondary degenerative events may also cause macular dysfunction, including cyst and hole formation, pigmentary changes, and schisis [89,95]. Traction from posterior components of the primary vitreous is a common cause. Occasionally, the macula may be normal [Figure 9].

Primary malformations of the optic nerve head include hypoplasia and dysplasia, of which the pathogenesis is still unclear [94,96]. Secondary changes include mild-to-marked tractional deformations.

Bilateral PFV or congenital non-attachment of the retina can also occur in association with a systemic disease, e.g., Norrie disease or Walker–Warburg syndrome. In these patients, severe primary undifferentiation of the neurosensory retina is characteristic [97,98].

Differentials of tractional retinal detachment in infants or children include FEVR, Norrie disease, incontinentia pigmenti, and retinoblastoma. Direct visualization of any component of the fetal vasculature is the best clue to diagnosing an anomaly associated with PFV correctly. PFV is typically unilateral. The implantation of the stalk is usually to the central posterior lens capsule, whereas in FEVR, Norrie disease, and incontinentia pigmenti, there is no stalk but rather a fold that usually runs to the temporal ora serrata. Retinoblastoma eyes are rarely microphthalmic and will have a mass with possible calcifications on ultrasound or CT scan of the orbits [99].

The natural history of severe forms of PFV is progression of fibrovascular dysplasia, leading to angle closure glaucoma, opacification of the cornea, cataract, intraocular hemorrhage, retinal detachment, and phthisis bulbi [87,98].

**Surgical techniques**

Indications for surgery include the presence of amblyogenic media opacity, progressive glaucoma secondary to angle closure, vitreoretinal traction, and RRD or progressive tractional RD. The aim of surgery is to clear any amblyogenic media opacity (cataract, hemorrhage) and relieve posterior vitreoretinal traction.

The decision to operate and preoperative counseling of outcomes should take into consideration a few factors – visual potential determined by the presence of congenital anomalies of the macula and optic nerve, cerebral function, patient age (duration of visual deprivation), and unilaterality or bilaterality.

Visual outcomes are largely dependent on anatomic outcomes and cortical visual development. Factors associated with poorer visual prognosis and lower chance of achieving form vision (defined as counting fingers, fix-and-follow, or better) include the presence of a significant component of posterior PFV, bilaterality, and microphthalmia [100].

Certain study groups have advocated that earlier surgery can result in improved visual function. Bosjolie and Ferrone [101] suggested that a period of retinal “physical plasticity” extends to at least 13 months of age and advocate for consideration of early vitrectomy in children with tractional RD and posterior PFV. In their study, all 10 patients who had surgery at 13 months of age or younger had...
reattachment of the retina with reversal of retinal dragging and decreased retinal folds. Notably, 9 of 10 patients were younger than 6 months of age at the time of surgery. Sixty percent had functional vision of 20/800 or better. This favorable functional visual result may be related to the development of vision after early intervention and early amblyopia treatment.

Vitrectomy with or without lensectomy is the surgery of choice to treat posterior PFV. For vitrectomy, the anterior translimbal approach is preferred by some compared to the posterior pars plicata/pars plana approach. This is an important consideration in microphthalmic eyes as the ora serrata may be anteriorly displaced, the pars plana may be absent, or the anterior retina may insert directly onto the pars plicata or ciliary body.\textsuperscript{[102,103]} In PFV, the peripheral retina and ciliary body may also be dragged anteriorly and centrally, increasing the risk of iatrogenic injury to these structures.\textsuperscript{[104,105]}

Some however advocate the posterior pars plicata approach to vitrectomy and lensectomy.\textsuperscript{[103,106,107]} This approach with earlier transection of the persistent hyaloid stalk may result in reduced disturbance of the cornea and anterior chamber angle, more complete removal of the lens cortex, and reduced anterior traction on the posterior retina. Control of bleeding of the transected fetal vessels is critical, and this can be achieved with intraocular diathermy. Traction on the ciliary body can be relieved with meticulous excision of the retrolental tissue and with radial cuts between the centrally dragged ciliary processes.

In eyes with non-axial lens opacification, Shaikh and Trese\textsuperscript{[108]} recommended dividing the stalk immediately on entry. After division of the stalk with hemostasis, vitreous is then removed with peeling of epiretinal membranes in the posterior pole. The authors believed that manipulation of the stalk by vitrectomy and

Figure 9: (a) Persistent posterior hyaloidal vessels extending from the disc to the lens, (b) B-scan ultrasound demonstrating the persistent posterior hyaloidal stalk, (c) Optical coherence tomography through the nerve and peripapillary retina showing traction from hyaloidal vessels causing mild tractional retinal detachment, (d) Advanced persistent fetal vasculature with closed funnel tractional retinal detachment.
diathermy before division can damage the lens capsule with resultant cataract formation.

Regardless of technique, maximum visual rehabilitation requires early surgery (during the critical period of visual development) and aggressive postoperative management of amblyopia.

**Rhegmatogenous/Exudative/Tractional Retinal Detachments**

**Familial exudative vitreoretinopathy**

Familial exudative vitreoretinopathy (FEVR) is a hereditary bilateral retinal vascular disorder first described by Criswick and Schepens in 1969. The most common mode of inheritance is autosomal dominant, although X-linked recessive and sporadic cases have also been reported. FEVR patients have a mutation in the Norrie disease gene. The mutation results in dysregulation of the Wnt-receptor: β-catenin pathway and has been associated with increased levels of VEGF. This explains the lifelong chronic nature of FEVR, characterized by exacerbation of exudation secondary to upregulated vascular activity.

FEVR is sometimes not recognized as it can resemble other ocular conditions, depending on the patient’s age and the stage of the disease. The phenotype of FEVR resembles a forme fruste of ROP, occurring in a larger and often term infant, without a history of low birth weight or oxygen supplementation. The primary abnormality is a cessation of peripheral vascular growth with subsequent abnormal angiogenesis. Systemic associations are absent.

The clinical classification is based on five stages [Table 2]. Pendergast and Trese divided eyes into groups according to severity of disease and the presence of and extent of RD, and further divided RD into those with a predominantly effusive (exudative) or predominantly tractional component.

Patients usually present with decreased vision in one or both eyes, strabismus, or are asymptomatic and the condition discovered on screening families of known patients. Clinical findings include pseudoexotropia secondary to macular ectopia, posterior subcapsular cataract, neovascular glaucoma, band keratopathy, and a peripheral zone of avascular retina. The peripheral zone of avascular retina is pathognomonic of FEVR. This leads to peripheral retinal neovascularization, peripheral retinal traction with temporal dragging, falciform folds, retinal detachment, and lipid exudation [Figure 10].

FEVR tends to be a variably progressive disorder, with detachments often occurring only in the first or

**Table 2: Clinical classification of familial exudative vitreoretinopathy**

| Stage 1: | Avascular retinal periphery without extra-retinal vascularization |
|---------|------------------------------------------------------------------|
| Without exudate | Stage 2: Avascular retinal periphery with extra-retinal vascularization |
| With exudate |
| Stage 3: Retinal detachment: Subtotal, not involving fovea |
| Primarily exudative |
| Primarily tractional |
| Stage 4: Retinal detachment: Subtotal, involving fovea |
| Primarily exudative |
| Primarily tractional |
| Stage 5: Retinal detachment, total |
| Open funnel |
| Closed funnel |

![Figure 10: (a) Familial exudative vitreoretinopathy – Wide field photograph showing peripheral exudation and traction with dragged disc, (b-e) Fundus fluorescein angiography of early, mid, and late phases demonstrating disc and peripheral retinal leakage with a zone of avascular peripheral retina](image-url)
management with pediatric ophthalmologists in the treatment of associated amblyopia. Finally, managing the expectations of anxious parents and pediatric patients can be difficult but essential to ensure continued follow-up to enhance final surgical outcomes.

**Acknowledgments**

We would like to acknowledge our Medical Imaging Specialists, Cynthia VandenHoven, BAA, CRA and Leslie D. MacKeen BSc, CRA, from the Ophthalmic Imaging Unit at the Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, for their contributions to the photographs in this chapter.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

The authors declare that there are no conflicts of interests of this paper.

**References**

1. Soliman MM, Macky TA. Pediatric rhegmatogenous retinal detachment. Int Ophthalmol Clin 2011;51:147-71.
2. Soheilian M, Ramezani A, Malib M, Yaseri M, Ahmadieh H, Dehghan MH, et al. Clinical features and surgical outcomes of pediatric rhegmatogenous retinal detachment. Retina 2009;29:545-51.
3. Chen SN, Jiunn-Feng H, Te-Cheng Y. Pediatric rhegmatogenous retinal detachment in Taiwan. Retina 2006;26:410-4.
4. Chang PY, Yang CM, Yang CH, Huang JS, Ho TC, Lin CP, et al. Clinical characteristics and surgical outcomes of pediatric rhegmatogenous retinal detachment in Taiwan. Am J Ophthalmol 2005;139:1067-72.
5. Gonzalez CR, Singh S, Yu F, Kreiger AE, Gupta A, Schwartz SD, et al. Pediatric rhegmatogenous retinal detachment: Clinical features and surgical outcomes. Retina 2009;29:847-52.
6. Wang NK, Tsai CH, Chen YP, Yeung L, Wu WC, Chen TL, et al. Pediatric rhegmatogenous retinal detachment in East Asians. Ophthalmology 2005;112:1890-5.
7. Fivgas GD, Capone A Jr. Pediatric rhegmatogenous retinal detachment. Retina 2001;21:101-6.
8. Lee RW, Mayer EJ, Markham RH. The aetiology of paediatric rhegmatogenous retinal detachment: 15 years experience. Eye (Lond) 2008;22:636-40.
9. Daniel R, Kanski J, Glasspool M. Retinal detachment in children. Trans Ophthalmol Soc U K 1974;94:325-34.
10. Winslow RL, Tasman W. Juvenile rhegmatogenous retinal detachment. Ophthalmology 1978;85:667-18.
11. Cameron ME. Non-traumatic dialysis in the young. Br J Ophthalmol 1960;44:541-6.
12. Meier P, Wiedemann P. Surgical retina, Complicated forms of retinal detachment. In: Ryan SJ, editor. Surgery for Pediatric Vitreoretinal Disorders. InjuriesIndirect Injury. Part 1. 5th ed. Vol. 3, Sec. 3. Ch. 115. 1941-42; 2012.
13. Chignell AH. Retinal dialysis. Br J Ophthalmol 1973;57:572-7.
14. Häring G, Wiegens B. Long-term results after scleral buckling surgery in complicated juvenile retinal detachment without proliferative vitreoretinopathy. Retina 1998;18:501-5.
15. Wang NK, Chen YP, Yeung L, Chen KJ, Chao AN, Kuo YH, et al. Traumatic pediatric retinal detachment following open globe surgery. Ophthalmology 2009;116:727-32.
injury. Ophthalmologica 2007;221:255-63.

16. Warder D, Muni R, Yong SO, Kertes PJ. Pneumatic Retinopexy as a Treatment for Rhegmatogenous Retinal Detachment in Paediatric Patients. ASRS; 2015.

17. Weinberg DV, Lyon AT, Greenwald MJ, Mets MB. Rhegmatogenous retinal detachments in children: Risk factors and surgical outcomes. Ophthalmology 2003;110:1708-13.

18. Soliman MM, Macky T. Pediatric rhegmatogenous retinal detachment: Clinical features, management and visual outcome. EVRS Educ Electr J 2005;2:5-12.

19. Sticker GB, Belau PG, Farrell PJ, Jones JD, Pugh DG, Steinberg AG, et al. Hereditary progressive arthro-ophthalmpathy. Mayo Clin Proc 1965;40:433-55.

20. Sneed SC, Yates JR. Clinical and molecular genetics of stickler syndrome. J Med Genet 1999;36:353-9.

21. Richards AJ, Meredith S, Poulson A, Bearcroft P, Crossland G, Baguley DM, et al. A novel mutation of COL2A1 resulting in dominantly inherited rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 2005;46:663-8.

22. Sticker GB, Pugh D. Hereditary progressive arthro-ophthalmpathy, II: Additional observations on vertebral abnormalities, a hearing defect, and a report of a similar case. Mayo Clin Proc 1967;42:495-500.

23. Sticker GB, Hughes W, Houchin P. Clinical features of hereditary progressive arthro-ophthalmpathy (Stickler syndrome): A survey. Genet Med 2001;3:192-6.

24. Liberfarb RM, Levy HP, Rose PS, Wilkin DJ, Balog JZ, et al. The Stickler syndrome: Genotype/phenotype correlation in 10 families with Stickler syndrome resulting from seven mutations in the type II collagen gene locus COL2A1. Genet Med 2003;5:21-7.

25. Parma ES, Körkkö J, Hagler WS, Ala-Kokko L. Radial perivascular retinal degeneration and retinal detachment. Arch Ophthalmol 1973;89:176-85.

26. Abeyriri P, Bunce C, da Cruz L. Outcomes of surgery for retinal detachment in patients with Stickler syndrome: A comparison of two sequential 20-year cohorts. Graefes Arch Clin Exp Ophthalmol 2007;245:1633-8.

27. Ang A, Poulson AV, Goodburn SF, Richards AJ, Scott JD, Sneed MP, et al. Retinal detachment and prophylaxis in type 1 Stickler syndrome. Ophthalmology 2008;115:164-8.

28. Donoso LA, Edwards AO, Frost AT, Ritter R, Ahmad NN, Vrabec T, et al. Identification of a stop codon mutation in exon 2 of the collagen 2A1 gene in a large Stickler syndrome family. Am J Ophthalmol 2002;134:720-7.

29. Scott JD. Giant retinal tears of the retina. Trans Ophthalmol Soc U K 1975;95:1142-4.

30. Billington BM, Leaver PK, McLeod D. Management of retinal detachment in the Wagner-Stickler syndrome. Trans Ophthalmol Soc U K 1985;105(Plt 8):875-9.

31. Hirose T, Lee KY, Schepens CL. Wagner’s hereditary vitreoretinal degeneration and retinal detachment. Arch Ophthalmol 1973;89:176-85.

32. Remulla JF, Tolentino FI. Retinal detachment in Marfan’s syndrome. Int Ophthalmol Clin 2001;41:235-40.

33. Wheatley HM, Brubloui EJ, Flowers BE, Maumenee IH, Azar D, Pyeritz RE, et al. Immunohistochemical localization of fibrillin in human ocular tissues. Relevance to the Marfan syndrome. Arch Ophthalmol 1985;103:103-9.

34. Leoes BL, Dietz HC, Braverman AC, Callewaert BL, De Baecker J, Deverve EB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476-85.

35. Pyeritz RE, McKusick VA. The Marfan syndrome: Diagnosis and management. N Engl J Med 1979;300:772-7.

36. Magid D, Pyeritz RE, Fishman EK. Musculoskeletal manifestations of the Marfan syndrome: Radiologic features. AJR Am J Roentgenol 1990;155:99-104.

37. Maumenee IH. The eye in the Marfan syndrome. Trans Am Ophthalmol Soc 1981;79:684-733.

38. Cross HE, Jensen AD. Ocular manifestations in the Marfan syndrome and homocystinuria. Am J Ophthalmol 1973;75:405-20.

39. Jarrett WH 2nd. Dislocation of the lens. A study of 166 hospitalized cases. Arch Ophthalmol 1967;78:289-96.

40. Sharma T, Gopal L, Shannugam MP, Bhende PS, Agrawal R, Shetty NS, et al. Retinal detachment in Marfan syndrome: Clinical characteristics and surgical outcome. Retina 2002;22:423-8.

41. Abboud EB. Retinal detachment surgery in Marfan’s syndrome. Retina 1998;18:405-9.

42. Allen RA, Straatsma BR, Apt L, Hall MO. Ocular manifestations of the Marfan syndrome. Trans Am Acad Ophthalmol Otolaryngol 1967;71:18-38.

43. Wei Y, Li Y, Chen F. Vitrectomy treatment of retinal detachments related to choroidal coloboma involving the disk. Retina 2014;34:1091-5.

44. Jesberg DO, Schepens CL. Retinal detachment associated with coloboma of the choroid. Arch Ophthalmol 1961;65:163-73.

45. Daunenbach DR, Ruttm MS, Pulido JS, Kevey RV. Chorioretinal colobomas in a pediatric population. Ophthalmology 1998;105:1455-8.

46. Gopal L, Khan B, Jain S, Prakash VS. A clinical and optical coherence tomography study of the margins of choroidal colobomas. Ophthalmology 2007;114:571-80.

47. Gopal L. A clinical and optical coherence tomography study of choroidal colobomas. Curr Opin Ophthalmol 2008;19:248-54.

48. Gopal L, Badrinath SS, Sharma T, Farikh SN, Shannugam MS, Bhende PS, et al. Surgical management of retinal detachments related to coloboma of the choroid. Ophthalmology 1998;105:804-9.

49. Wang K, Hilton GF. Retinal detachment associated with coloboma of the choroid. Trans Am Ophthalmol Soc 1985;83:49-62.

50. Patnaik B, Kalsi R. Retinal detachment with coloboma of the choroid. Indian J Ophthalmol 1981;29:345-9.

51. Gopal L, Kini MM, Badrinath SS, Sharma T. Management of retinal detachment with choroidal coloboma. Ophthalmology 1991;98:1622-7.

52. Hotta K, Hirakata A, Hida T. The management of retinal detachments associated with choroidal colobomas by vitrectomy with cyanoacrylate retinopexy. Jpn J Ophthalmol 1998;42:323-6.

53. Jalali S, Das T. Selection of surgical technique for retinal detachment with coloboma of the choroid. Indian J Ophthalmol 1994;42:27-30.

54. Gevers M. Temporary use of silicone oil in the treatment of special cases of retinal detachment. Ophthalmologica 1983;187:202-9.

55. McDonald HR, Lewis H, Brown G, Sipperley JO. Vitreous surgery for retinal detachment associated with choroidal coloboma. Arch Ophthalmol 1991;109:1399-402.

56. Coats G. Forms of retinal disease with massive exudation. R Lond Ophthalmic Hosp Rep 1908;17:440-525.

57. Harris GS. Coats’ disease, diagnosis and treatment. Can J Ophthalmol 1970;5:311-20.

58. Harris GS. Coats’ disease, diagnosis and treatment. Mod Probl Ophthalmol 1972;10:277-85.

59. Black GC, Perven R, Bonshek R, Cahill M, Clayton-Smith J, Lloyd LC, et al. Coats’ disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: A role for norrin in retinal angiogenesis. Hum Mol Genet 1999;8:2031-5.

60. Morris B, Foot B, Mulvihill A. A population-based study of Coats disease in the United Kingdom I: Epidemiology and clinical features at diagnosis. Eye (Lond) 2010;24:1797-801.

61. Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of Coats disease in 150 cases: The 2000 San Francisco Gifford memorial lecture. Am J Ophthalmol 2001;131:561-7.
Outcomes of surgical (pars plicata and
85. Ramasubramanian A, Shields CL. Bevacizumab for coats' disease
83. Kaul S, Uparkar M, Mody K, Walinjkar J, Kothari M, Natarajan S,
82. Lin CJ, Hwang JF, Chen YT, Chen SN. The effect of intravitreal
81. Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG. Current
78. Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial
76. Yoshizumi MO, Kreiger AE, Lewis H, Foxman B, Hakakha BA.
75. Devenyi RG. The use of perfluorocarbon liquid in the surgical
74. Ridley ME, Shields JA, Brown GC, Tasman W. Coats' disease.
72. Schmidt‑Erfurth U, Lucke K. Vitreoretinal surgery in advanced
71. Mulvihill A, Morris B. A population‑based study of coats disease
68. Senft SH, Hidayat AA, Cavender JC. Atypical presentation of
67. Mafee MF, Goldberg MF, Cohen SB, Gotsis ED, Safran M,
66. Edward DP, Mafee MF, Garcia‑Valenzuela E, Weiss RA. Coats'
65. Atta HR, Watson NJ. Echographic diagnosis of advanced Coats' disease.
64. Jones JH, Kroll AJ, Lou PL, Ryan EA. Coats' disease. Int
63. Reichstein DA, Recchia FM. Coats disease and exudative retinal detachment. Retina 2016;36:156‑62.
62. Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: The 2000 proctor lecture. Am J Ophthalmol 2001;131:572‑83.
61. Reinstein DA, Recchia FM. Coats disease and exudative retinopathy. Int Ophthalmol Clin 2011;51:93‑112.
60. Jones JH, Kroll AJ, Lou PL, Ryan EA. Coats’ disease. Int Ophthalmol Clin 2001;41:189‑98.
59. Atta HR, Watson NJ. Echographic diagnosis of advanced Coats’ disease. Eye (Lond) 1992;6( Pt 1):80‑5.
58. Edward DP, Mafee MF, Garcia‑Valenzuela E, Weiss RA. Coats’ disease and persistent hyperplastic primary vitreous. Role of MR imaging and CT. Radied Clin North Am 1998;36:1119‑31, x.
57. Mafee MF, Goldberg MF, Cohen SB, Gotsis ED, Safran M, Chekuri L, et al. Magnetic resonance imaging versus computed tomodraphy of leukocoric eyes and use of in vitro proton magnetic resonance spectroscopy of retinoblastoma. Ophthalmology 1989;96:965‑75.
56. Senth SH, Hidayat AA, Cavender JC. Atypical presentation of coats disease. Retina 1994;14:36‑8.
55. Egerer I, Tasman W, Tomer TT. Coats disease. Arch Ophthalmol 1974;92:109‑12.
54. Theodosiadis GP, Bairaktaris‑Kouris E, Kouris T. Evolution of Leber’s miliary aneurysms: A clinicopathological study. J Pediatr Ophthalmol Strabismus 1979;16:364‑70.
53. Mulvihill A, Morris B. A population‑based study of coats disease in the United Kingdom II: Investigation, treatment, and outcomes. Eye (Lond) 2010;24:1802‑7.
52. Schmidt‑Erfurth U, Lucke K. Vitreoretinal surgery in advanced Coat’s disease. Ger J Ophthalmol 1995;4:32‑6.
51. Adam RS, Kertes PJ, Lam WC. Observations on the management of coats’ disease: Less is more. Br J Ophthalmol 2007;91:303‑6.
50. Ridley ME, Shields JA, Brown GC, Tasman W. Coats’ disease. Evaluation of management. Ophthalmology 1982;89:1381‑7.
49. Devenyi RG. The use of perfluorocarbon liquid in the surgical repair of a bullous retinal detachment secondary to Coats’ disease. Can J Ophthalmol 1998;33:385‑6.
48. Yoshizumi MO, Kreiger AE, Lewis H, Foxman B, Hakakha BA. Vitrectomy techniques in late‑stage coats’‑like exudative retinal detachment. Doc Ophthalmol 1995;90:387‑94.
47. Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in coats disease by adjuvant intravitreal triamcinolone: Effects and complications. Br J Ophthalmol 2010;94:606‑10.
46. Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in coats disease: Rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol 2007;245:1387‑8.
45. Kase S, Rao NA, Yoshikawa H, Fukushima J, Noda K, Kanda A, et al. Expression of vascular endothelial growth factor in eyes with coats’ disease. Invest Ophthalmol Vis Sci 2013;54:57‑62.
44. Ghorbanian S, Jaulim A, Chatziralli IP. Diagnosis and treatment of coats’ disease: A review of the literature. Ophthalmologica 2012;227:175‑82.
43. Sigler EJ, Randolph JC, Calzada JJ, Wilson MW, Haik BG. Current management of coats disease. Surv Ophthalmol 2014;59:30‑46.
42. Lin CJ, Hwang JF, Chen YT, Chen SN. The effect of intravitreal bevacizumab in the treatment of coats disease in children. Retina 2010;30:617‑22.
41. Kaul S, Uparkar M, Mody K, Walinjkar J, Kothari M, Natarajan S, et al. Intravitreal anti‑vascular endothelial growth factor agents as an adjunct in the management of coats’ disease in children. Indian J Ophthalmol 2010;58:76‑8.
40. Stanga PE, Jabarsansri H, Bindra MS, Gil‑Martinez M, Biswas S. Transcleral drainage of subretinal fluid, anti‑vascular endothelial growth factor, and wide‑field imaging‑guided laser in coats exudative retinal detachment. Retina 2016;36:156‑62.
39. Ramasubramanian A, Shields CL. Bevacizumab for coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 2012;96:356‑9.
108. Shaikh S, Trese MT. Lens-sparing vitrectomy in predominantly posterior persistent fetal vasculature syndrome in eyes with nonaxial lens opacification. Retina 2003;23:330-4.

109. Criswick VG, Schepens CL. Familial exudative vitreoretinopathy. Am J Ophthalmol 1969;68:578-94.

110. Gow J, Oliver GL. Familial exudative vitreoretinopathy. An expanded view. Arch Ophthalmol 1971;86:150-5.

111. Canny CL, Oliver GL. Fluorescein angiographic findings in familial exudative vitreoretinopathy. Arch Ophthalmol 1976;94:1114-20.

112. van Nouhuys CE. Signs, complications, and platelet aggregation in familial exudative vitreoretinopathy. Am J Ophthalmol 1991;111:34-41.

113. Zhao S, Overbeek PA. Elevated TGFbeta signaling inhibits ocular vascular development. Dev Biol 2001;237:45-53.

114. Pendergast SD, Trese MT. Familial exudative vitreoretinopathy. Results of surgical management. Ophthalmology 1998;105:1015-23.

115. Regillo CD. Familial exudative vitreoretinopathy. In: Guyer DR, Yannuzzi LA, Chang S, Shields JA, Green WR, editors. Retina-Vitreous-Macula. Vol. 1. Philadelphia, PA: W.B. Saunders Company; 1999. p. 421-430.

116. Shukla D, Singh J, Sudheer G, Soman M, John RK, Ramasamy K, et al. Familial exudative vitreoretinopathy (FEVR). Clinical profile and management. Indian J Ophthalmol 2003;51:323-8.

117. Ober RR, Bird AC, Hamilton AM, Sehmi K. Autosomal dominant exudative vitreoretinopathy. Br J Ophthalmol 1980;64:112-20.

118. Quiram PA, Drenser KA, Lai MM, Capone A Jr., Trese MT. Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina 2008;28:58-12.

119. Tagami M, Kusuhara S, Honda S, Tsukahara Y, Negi A. Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:1787-9.

120. Shubert A, Tasman W. Familial exudative vitreoretinopathy: Surgical intervention and visual acuity outcomes. Graefes Arch Clin Exp Ophthalmol 1997;235:490-3.

121. Glazer LC, Maguire A, Blumenkranz MS, Trese MT, Green WR. Improved surgical treatment of familial exudative vitreoretinopathy in children. Am J Ophthalmol 1995;120:471-9.